Alkem Laboratories cash flow

Latest FY26

Cash from operations: ₹1,963cr+2.6% on FY25
Capital spending: ₹617cr−8.6% on FY25
Free cash flow: ₹1,346cr+8.8% on FY25
Cash from financing: −₹503cr−₹811 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	382	357	299	310
	—	161	122	112	107
	—	−392	−359	−276	−171
	—	0.0	−0.2	−0.2	−0.2
	—	10.9	−41.9	0.0	0.0
	—	4.9	0.0	0.0	0.0
	—	−16.0	11.2	58.9	−40.6
	—	−14.5	14.6	189	118
	—	−247	−261	−73.4	473
	—	−329	−219	−222	−135
	—	−87.5	25.0	0.0	0.0
	—	0.0	0.0	−135	−77.0
	—	121	217	525	14.5
	—	127	24.2	−146	50.6
Cash from operating activities
	2,872	2,871	2,527	2,023	1,305
	—	−279	−110	332	651
	—	2,592	2,417	2,355	1,956
	—	−0.1	0.0	0.0	0.0
	—	629	504	407	273
	—	1,963	1,913	1,948	1,683
Cash from investing activities
	—	617	676	259	233
	—	130	40.8	72.5	3.2
	—	7,451	5,727	3,679	0.0
	—	5,943	4,715	2,618	−218
	—	0.1	0.2	0.2	0.2
	—	328	348	239	147
	—	0.0	0.0	0.0	413
	—	−1,667	−1,299	−1,009	113
Cash from financing activities
	—	0.0	0.0	0.0	161
	—	314	288	40.0	−1,269
	—	65.4	482	521	9.5
	—	41.0	31.7	0.0	23.8
	—	—	—	32.3	0.0
	—	123	80.6	91.3	90.5
	—	614	505	540	530
	—	26.2	0.0	0.0	0.0
	—	−503	−811	−1,145	−1,761
	—	−208	−197	−205	34.5
	—	−14.5	10.5	−2.1	7.1
	—	−222	−186	−207	41.6
	—	—	—	66.3	274
Reference items
	3,032	3,005	2,512	2,245	1,609
	20.1%	20.4%	19.4%	17.7%	13.9%
	1,346	1,346	1,237	1,689	1,450
	—	1,783	1,005	1,415	—
	₹112.57	₹112.57	₹103.49	₹141.26	₹121.25
	45.12×	—	—	—	—
	—	0.83×	0.86×	1.08×	1.67×
	—	629	504	407	273
	—	123	80.6	91.3	90.5

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ALKEM₹5,079.00

Alkem Laboratories Ltd.

· Pharma & Health

₹ CrorePeersMANKIND TORNTPHARM IPCALAB LUPIN FORTIS AUROPHARMA LAURUSLABS BIOCONMcap ₹60,719 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	310.4	299.3	357.2	382.1	—
+ Finance Costs	107.4	112.4	121.7	160.8	—
+ Interest Income	-171.1	-275.8	-358.8	-391.6	—
+ Dividend Income	-0.2	-0.2	-0.2	0.0	—
+ Fair Value (Gains) / Losses	0.0	0.0	-41.9	10.9	—
+ Share-based Payments	0.0	0.0	0.0	4.9	—
+ Unrealised FX (Gain) / Loss	-40.6	58.9	11.2	-16.0	—
+ Other Reconciling Items	118.5	188.9	14.6	-14.5	—
Changes in Working Capital
+ Inventories	473.4	-73.4	-261.2	-247.3	—
+ Trade Receivables — Current	-134.7	-222.0	-218.6	-328.9	—
+ Other Current Assets	0.0	0.0	25.0	-87.5	—
+ Other Non-current Assets	-77.0	-135.1	0.0	0.0	—
+ Trade Payables — Current	14.5	525.3	216.7	121.4	—
+ Provisions — Current	50.6	-146.5	24.2	127.1	—
Cash from Operating Activities
Profit Before Tax (per I/S)	1,304.8	2,023.1	2,527.0	2,870.9	2,871.9
+ Total Adjustments (incl. Working Capital)	651.1	331.9	-110.2	-278.8	—
Cash from Operations (pre-tax)	1,955.9	2,355.0	2,416.9	2,592.1	—
+ Dividends Received — Operating	0.0	0.0	0.0	-0.1	—
+ Income Taxes Paid	273.4	406.9	504.0	629.0	—
Cash from Operating Activities	1,682.5	1,948.1	1,912.8	1,963.0	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	232.9	259.3	675.6	617.3	—
+ Disp of Fixed Assets	3.2	72.5	40.8	130.3	—
+ Acq of Other Long-term Assets	0.0	3,679.3	5,726.9	7,451.1	—
+ Disp of Other Long-term Assets	-217.5	2,618.1	4,715.1	5,943.1	—
+ Dividends Received — Investing	0.2	0.2	0.2	0.1	—
+ Interest Received — Investing	146.9	239.3	347.7	327.6	—
+ Other Inflows / (Outflows) — Investing	413.0	0.0	0.0	0.0	—
Cash from Investing Activities	112.8	-1,008.5	-1,298.8	-1,667.2	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	161.5	0.0	0.0	0.0	—
+ Proceeds from Borrowings	-1,269.0	40.0	287.9	314.0	—
+ Repayment of Borrowings	9.5	520.9	482.0	65.4	—
+ Payment of Lease Liabilities	23.8	0.0	31.7	41.0	—
+ Payment of Finance Lease Liabilities	0.0	32.3	—	—	—
+ Interest Paid	90.5	91.3	80.6	123.5	—
+ Dividends Paid	529.5	540.5	504.6	613.7	—
+ Other Inflows / (Outflows) — Financing	0.0	0.0	0.0	26.2	—
Cash from Financing Activities	-1,760.8	-1,145.0	-811.0	-503.4	—
Net Changes in Cash (pre-FX)	34.5	-205.4	-196.9	-207.6	—
+ Effect of FX Rate Changes on Cash	7.1	-2.1	10.5	-14.5	—
Net Changes in Cash	41.6	-207.5	-186.4	-222.0	—
Closing Cash	273.8	66.3	—	—	—
Reference Items
EBITDA	1,609.5	2,245.5	2,512.2	3,005.2	3,032.2
EBITDA Margin %	13.88	17.73	19.38	20.43	20.11
Free Cash Flow (CFO − Capex)	1,449.6	1,688.8	1,237.2	1,345.8	1,345.8
Free Cash Flow to Equity	—	1,414.8	1,005.4	1,783.0	—
Free Cash Flow per Basic Share	121.25	141.26	103.49	112.57	112.57
Price to Free Cash Flow	—	—	—	—	45.12
Cash Flow to Net Income	1.67	1.08	0.86	0.83	—
Cash Paid for Taxes	273.4	406.9	504.0	629.0	—
Cash Paid for Interest	90.5	91.3	80.6	123.5	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.